U.S., Aug. 1 -- ClinicalTrials.gov registry received information related to the study (NCT07096999) titled 'SPECT/CT Imaging for Dosimetry in 177Lu-PSMA-617 (Pluvicto) Therapy' on July 08.
Brief Summary: This study is being performed to establish the association between absorbed dose to tumor and response and absorbed dose to normal organs and toxicity following Lu177-PSMA radioligand therapy
Study Start Date: Jan. 23
Study Type: OBSERVATIONAL
Condition:
Metastatic Castration-Resistant Prostate Carcinoma
Intervention:
OTHER: Non-Interventional Study
Non-interventional study
Recruitment Status: RECRUITING
Sponsor: University of Michigan Rogel Cancer Center
Disclaimer: Curated by HT Syndication....